BioCentury
ARTICLE | Distillery Therapeutics

HAS2 and NOTCH1 identified as targets in liver fibrosis induced by hepatitis B, hepatitis C and NASH

June 19, 2019 8:06 PM UTC

INDICATION: Liver fibrosis; non-alcoholic steatohepatitis (NASH)...